Borderline CD30+ cutaneous lymphoproliferative disorder: report of a case with expression of cytotoxic markers and response to clarithromycin.
CD30+ cutaneous lymphoproliferative disorders (CLPDs) are usually characterized by a benign clinical course. The prognostic value of cytotoxic markers in these lymphomas has not been evaluated in large series. We describe a case of borderline CD30+ CLPD with cytotoxic phenotype, presenting in a 22-year-old male patient as an ulcer on the forearm. He reported having had similar ulcers on the buttock and thigh that spontaneously regressed over the course of 1 year. The lesion resolved with a single course of clarithromycin; a subsequent lesion, too, responded to clarithromycin, and no recurrences or systemic involvement have been documented in the 9-month follow-up. A conservative approach in the management of CD30+ CLPD is recommended. We believe that the anti-inflammatory and apoptotic effects of clarithromycin on T cells may have hastened the remission process.
Ponte
Pedro
P
Department of Dermatology, Hospital dos Capuchos, Centro Hospitalar de Lisboa Central, Lisbon, Portugal. pedrofponte@gmail.com
Serrão
Vasco
V
Viana
Isabel
I
Vale
Esmeralda
E
João
Alexandre
A
Cerroni
Lorenzo
L
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D017291:Clarithromycin / Q000627:therapeutic use*; D006801:Humans; D017730:Ki-1 Antigen / Q000378:metabolism; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D008297:Male; D012878:Skin Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D014408:Biomarkers, Tumor; D017730:Ki-1 Antigen; D017291:Clarithromycin